Publication: Biomarkers Have Higher Diagnostic and Prognostic Potential Than Other Tools, page-17

From my experience, preclinical and phase 1 trial will normally hard to attract small, medium or large pharma to join and collaborate. Those are only basic research, if you google scholar, you will find lots and lots of biochemical that can potentially be drug targets. Many end up as failure. Midkine's plethora of research over the last decade, is not the only thing that is so. There are many cytokine like midkine being studied as well, some in university, some already in clinical stage....they all share one common thing, it take hell long of time (at least a decade or two) to reach the market.